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The prevalence of infection with human T-cell lympho-
tropic virus type 1 (HTLV-1) in blood donors from Israel is 1 
infection/100,000 persons. In donors originating from East-
ern Europe, the Middle East, and Latin America, prevalenc-
es are 7.7, 14.6, and 20.4, respectively. HTLV-1 prevalence 
may be high outside areas where HTLV-1 previously was 
known to be endemic.  
H
uman T-cell lymphotropic virus type 1 (HTLV-1) is 
prevalent mostly in Japan, Africa, the Caribbean Is-
lands, and South America (1,2). Known HTLV-1 modes of 
transmission include vertical transmission (predominantly 
through breastfeeding), transverse transmission (sexual in-
tercourse), transfusion of infected cellular blood products, 
and sharing of needles and syringes (1,2). Because of re-
ports of HTLV-1–associated diseases in Mashhadi Jews, 
the Israeli national blood services, Magen David Adom, 
began screening all blood units for HTLV-1 antibodies in 
1995. However, the prevalence of HTLV-1 infection in the 
general Israeli population has not yet been defined.
Israel is an immigration state, providing a unique op-
portunity to examine the prevalence of HTLV-1 infection 
according  to  donors’  countries  of  origin.  This  informa-
tion may reflect the distribution of HTLV-1 within the re-
spective countries of origin, some of which have not had 
HTLV-1 serosurveys performed.
The Study
Blood donation in Israel is voluntary and does not in-
volve any monetary benefit. Using records from Magen 
David Adom, we registered age, sex, country of birth, and 
maternal and paternal countries of birth once for each do-
nor, regardless of the number of blood units donated.
From 1995 through 1998, donors were screened for an-
tibodies against HTLV-1 and HTLV-2 by standard ELISA 
(Abbott HTLV-1/HTLV-2 enzyme immunoassay; Abbott 
Laboratories, Abbott Park, IL, USA). Since 1998, testing 
has  been  performed  by  chemiluminescent  immunoassay 
with the PRISM assay (Abbott Laboratories). The confir-
matory assay was Western blot HTLV Blot 2.4 (Genelabs 
Diagnostics, Singapore Science Park, Singapore).
On the basis of virus transmission modes, we devel-
oped an algorithm for identifying the ethnic origin of both 
HTLV-1–positive  and  HTLV-1–negative  blood  donors 
(Figure 1). We considered infection to be acquired in Is-
rael when the donor and both parents were born in Israel. 
We considered infection to be acquired outside Israel when 
the donor or 1 parent was born outside Israel. When the 
donor was born in Israel and the mother was born outside 
Israel, country of origin was considered the mother’s coun-
try of birth. When the donor and the mother were born in 
Israel, but the father was born outside Israel, country of ori-
gin was considered the father’s country of birth. Detailed 
classification of geographic origin of blood donors (both 
HTLV-1 positive and HTLV-1 negative) is given in the 
online Technical Appendix (available from www.cdc.gov/
EID/content/15/7/1116-Techapp.pdf).
Data were analyzed by using Microsoft Access (Micro-
soft, Redmond, WA, USA) and Epi Info (Centers for Dis-
ease Control and Prevention, Atlanta, GA, USA); statistical 
analysis was conducted by using χ2 analysis of contingency 
tables. The odds ratio (OR) and 95% confidence interval 
were calculated. Age was described as mean ± standard de-
viation. The Chaim Sheba Medical Center human subjects 
research review board approved this study.
From January 9, 1995, through December 31, 2003, a 
total of 1,256,669 blood donors were screened for HTLV-1 
infection in Israel. Of these, 73 HTLV-1 carriers were iden-
tified, for an overall prevalence of 5.8 infections per 100,000 
donors. Average age at diagnosis was 39.4 ± 11.9 years; 48 
(66%) were men (compared with 72% of all blood donors; p 
= 0.3125). All HTLV-1–positive donors had negative sero-
logic results for HTLV-2, human immunodeficiency virus, 
hepatitis C virus, and hepatitis B surface antigen. HTLV-1 
carriers originated from 20 countries (Table).
ORs for HTLV-1 carriers varied by geographic origin 
of donor (Figure 2). Donors from Middle Eastern and East-
ern European countries were at highest risk for HTLV-1 
carriage.
Conclusions
The diversity of the population in Israel, combined with 
systematic screening of blood donors, enabled us to exam-
ine the global epidemiology of HTLV-1 infection. One or 
both parents of at least 67% of Jews in Israel were born 
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outside Israel. Thirteen percent immigrated from Asia, 16% 
from Africa, and 36% from Europe and the Americas (3). 
We believe that blood donors are representative of healthy 
persons in the general population of the country because ap-
proximately one third of the population are blood donors.
The prevalence of HTLV-1 infection among blood 
donors in Israel was 5.8/100,000 but varied depending on 
donors’ geographic origins. In blood donors born in Is-
rael, the prevalence of HTLV-1 infection was 1/100,000, 
comparable  to  and  even  lower  than  the  prevalence  of 
HTLV-1 in blood donors from northern Europe (online 
Technical  Appendix).  Unfortunately,  information  from 
many countries is either lacking or unrepresentative. We 
found a similar prevalence of HTLV-1 infection in Jewish 
immigrants from known HTLV-1 endemic countries to 
what is known in their native countries. For example, the 
reported prevalence in blood donors in Latin American 
countries ranged from 30/100,000 to 1,000/100,000 (on-
line Technical Appendix); our study found a prevalence 
of 20/100,000.
In  donors  from  the  Middle  East,  we  found  a  high 
prevalence  of  HTLV-1  infection  in  blood  donors  from 
Iran  (50.4/100,000),  Turkey  (16.0/100,000),  and  Iraq 
(10.2/100,000). Of those countries, only Iran can provide 
information about HTLV-1 prevalence, and those data are 
limited to Mashhad (4). Our survey was performed after the 
initial report of HTLV-1–associated disorders in Israelis 
born in or originating from Mashhad (5). This example can 
highlight the role of immigrants as reflectors of the popula-
tions in their countries of origin. We found no systematic 
information about the epidemiology of HTLV-1 in the rest 
of Iran and neighboring countries. However, anecdotal re-
ports suggest that the infection exists in Kuwait, Turkmeni-
stan, and Georgia (6–8).
In persons from eastern Europe, we found a high prev-
alence  of  HTLV-1  carriage  in  blood  donors  originating 
from Romania (14.9/100,000), Russia (6.3/100,000), and 
the former Yugoslavia (62.9/100,000). Most of the litera-
ture does not consider eastern Europe endemic for HTLV-1 
infection (2). Particularly in Romania, HTLV-1 prevalence 
is considered low, and HTLV-1 positivity was attributed 
mainly to immigration from other countries (2). In a care-
ful review of the literature, we found only a few studies 
involving a small number of blood donors (online Tech-
nical Appendix). These studies support our findings and 
suggest that HTLV-1 is endemic in some eastern European 
countries. Several cases of adult T-cell leukemia have been 
described in patients of Romanian origin (9–14).
Our findings establish the need for rigorous screen-
ing of blood donors in suspected HTLV-1–endemic areas 
(Middle East and eastern Europe) and show the impact of 
immigrants or travelers as sentinels to the health problem 
in their country of origin. Our data also demonstrate high 
prevalence of HTLV-1 infection among those whose coun-
try of origin had been considered nonendemic for HTLV-1. 
Viral transmission could have occurred either from the non-
Jewish local population or from other Jewish communities 
in which HTLV-1 is endemic. We are not aware of immi-
gration waves of Jewish populations from Iran and Iraq to 
Eastern Europe and vice versa. In addition, the prevalence 
of HTLV-1 in blood donors from Israel is low. Therefore, it 
seems reasonable to conclude that our findings reflect local 
HTLV-1 endemicity in the country of origin.
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Donor birth country
Israel Outside Israel
Donor’s country of origin Donor’s mother’s birth country
Outside Israel Israel
Donor’s country of origin  Donor’s father’s birth country
Israel Outside Israel 
Donor’s country of origin  Donor’s country of origin = Israel 
Figure 1. Algorithm for identifying the geographic origin of Israeli 
blood donors.
Table. Prevalence of HTLV-1 in blood donors from different 
countries of origin, Israel, 1995–1998* 
Country 
No.
HTLV-1
carriers 
No. blood 
bank donors 
No. carriers/ 
100,000
donors
Iran 16 31,776 50.4
Romania 12 73,971 14.9
Iraq 7 68,857 10.2
Russian Federation 7 111,109 6.3
Turkey 4 25,054 16
Poland 3 70,172 4.3
Israel 3 294,342 1.0
Morocco 3 144,014 2.1
United States 3 49,204 6.1
Yugoslavia† 2 3,181 62.9
Uruguay 2 3,552 56.3
Argentina 2 20,898 9.6
Chile 2 2,101 95.2
Czechoslovakia† 1 11,149 9.0
Brazil 1 4,217 23.7
Niger 1 1
Ethiopia 1 3,412 29.3
Egypt 1 21,245 4.7
Yemen 1 36,052 2.8
Libya 1 21,427 4.7
*HTLV-1, human T-lymphotropic virus type 1. 
†Country no longer exists. Dr Stienlauf is head of the national clinic for HTLV-1 in-
fection at the Chaim Sheba Medical Center. His main research 
interests are travel medicine and tropical medicine.
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Odds ratio (95% CI)
0 0 (0.0) 2,605 (0.2) Oceania
5.5 3 (4.1) 54,474 (4.4) North 
America
0 0 (0.0) 13,800 (1.1) Asia
1 3 (4.1) 294,342 (23.7) Israel
0 0 (0.0) 87,335 (7.0) West 
Europe
2.2 5 (6.6) 227,542 (18.3) North 
Africa
7.7 25 (34.2)† 325,547 (26.3) East 
Europe
17.1 2 (2.7) 11,713 (0.9) Africa
14.6 28 (38.4)† 192,041 (15.4) Middle East 
20.4 7 (9.6)† 34,372 (2.8) Latin 
America 
Prevalence* No. (%) 
HTLV-1
No. (%) blood 
bank donors
Geographic 
origin
10–3 10–2 10–1 1 101 102 103
0.062 (0.0030–1.2)
0.2 (0.037–0.9)
0.3 (0.017–6.4)
2.1 (0.1–40.2)
2.2 (0.5–9)
7.5 (2.3–25)
8.1 (0.1–478.8)
14.3 (4.3–47.055)
20 (5.1–77.3)
Figure  2. Relative risk for human T-cell  lymphotropic  virus  type 
1  carriage  in  donors  from  different  geographic  origins.  Odds 
ratios (indicated by black boxes) are charted in logarithmic scale. 
Error bars indicate 95% confidence intervals (CI). *Per 100,000 
population; †p<0.05.
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